Total pharma industry venture financing deals in June 2019 worth $1.09bn were announced globally, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

The value marked a decrease of 11.8% over the previous month and a drop of 32.1% when compared with the last 12-month average, which stood at $1.6bn.

Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $757.12m. At the country level, the US topped the list in terms of deal value at $749.83m.

In terms of volumes, North America emerged as the top region for pharma industry venture financing deals globally, followed by Europe and then Asia-Pacific.

The top country in terms of venture financing deals activity in June 2019 was the US with 41 deals, followed by China with five and the UK with four.

In 2019, as of the end of June 2019, pharma venture financing deals worth $8.7bn were announced globally, marking a decrease of 29.5% year on year.

Pharma industry venture financing deals in June 2019: Top deals

The top five pharma industry venture financing deals accounted for 37.7% of the overall value during June 2019.

The combined value of the top five pharma industry venture financing deals stood at $409m, against the overall value of $1.09bn recorded for the month. The top announced pharma industry venture financing deal tracked by GlobalData in June 2019 was Alexandria Venture Investments, Altitude Life Science Ventures, ARCH Venture Partners, Boxer Capital, Illumina Ventures, Matrix Capital Management Company, Menlo Ventures, RTW Investments and Venrock’s $104m venture financing of Encoded Genomics.

In second place was the $80m venture financing of Oncologie by Korea Investment Partners, Nan Fung Life Sciences, Panacea Venture Healthcare Fund I, L.P and Pivotal bioVenture Partners and in third place was Alexandria Venture Investments, Altitude Life Science Ventures, ARCH Venture Partners, Biomatics Capital Partners, GV Management Co, Johnson & Johnson Innovation – JJDC, Mercury Fund, Polaris Partners, Premier Partners, The Scripps Research Institute and Vertex Ventures HC’s $76m venture financing of Blackthorn Therapeutics.

The $75m venture financing of Viela Bio by Barer & Son Capital, Cormorant Asset Management, Goldman Sachs & Co, HBM Healthcare Investments, Temasek Holdings (Private), Terra Magnum Capital Partners and Viking Global Investors and 3E Bioventures, Decheng Capital, Oriza Seed Venture Capital, SDIC Fund Management, Sherpa Healthcare Partners and South China Venture Capital’s venture financing of EpimAb Biotherapeutics for $74m held fourth and fifth positions, respectively.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.